Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Molecular and Clinical Oncology - United Kingdom
doi 10.3892/mco.2018.1553
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Toxic Epidermal Necrolysis

Medical Journal Armed Forces India
Medicine
2007English

Toxic Epidermal Necrolysis: Reply

Medical Journal Armed Forces India
Medicine
2007English

Lyell's Toxic Epidermal Necrolysis

BMJ
1967English

Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Efficacy of Target Therapy With Crizotinib in a Patient With Alk-Positive Advanced Gastric Cancer

Siberian Journal of Oncology
Cancer ResearchOncology
2020English

Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Zonisamide

Clinical Case Reports
Medicine
2017English

P2.01-109 Treatment Duration—A More Reasonable Definition to Evaluate the Efficacy of Crizotinib in ALK Positive Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Dramatic Response to Crizotinib in an ALK-Positive Adenocarcinoma Patient With Disseminated Intravascular Coagulation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

Paraneoplastic Pemphigus Mimicking Toxic Epidermal Necrolysis: An Underdiagnosed Entity?

JAAD Case Reports
Dermatology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy